Biotechnology

With over AUD$1M in sales from its first MDMA batch, Cortexa is validating Australia's pioneering move to legalize psychedelic-assisted therapy.

The life sciences analytics provider earned a top sustainability rating, signaling a shift where ESG performance is now critical for pharma partnerships.

Tempest Therapeutics raises up to $6M in a critical financing deal to advance its CAR-T pipeline, balancing promising clinical data with financial pressures.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

Ephicacy appoints biometrics SVP Jamie Powers and India Head Tyagi Swaminathan in a strategic push to dominate advanced clinical trial analytics.

A key preclinical success in a $570M partnership advances a novel therapy designed to reset the immune system for patients with lupus, MS, and arthritis.

Lifecore Biomedical secures its third major manufacturing deal in five months, signaling a strategic shift that could reshape the aesthetics supply chain.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

A major chemical firm is raising prices, revealing how Red Sea disruptions and market volatility directly impact costs for pharma, personal care, and more.

With a new grant, Tessera Therapeutics is advancing its novel Gene Writing platform to engineer a scalable, single-shot cure for HIV. But can it work?

With major expansions in the US and Europe, Cambrex aims to lead the high-stakes race for specialized API production, targeting next-generation therapies.

A major labor dispute at the world's top drug manufacturer threatens global supply chains, with a union pointing to deep-seated governance issues at Samsung.

Pharma giant Sanofi inks a massive deal for Kali Therapeutics' KT501, a novel T-cell engager aiming to reset the immune system in autoimmune diseases.

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

A top university and a global clinical research firm unite to slash drug development timelines, aiming to bring innovative therapies to patients faster.

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

RenovoRx sets a key update call, juggling early RenovoCath device sales with its pivotal Phase III pancreatic cancer trial, a beacon for patients.

With six top honors at a key summit, Fortis Healthcare highlights India's rapid growth as a trusted, affordable destination for advanced medical treatment.